Các bài viết có thể truy cập công khai - Jarushka NaidooTìm hiểu thêm
Không có ở bất kỳ nơi nào: 3
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
DB Johnson, KL Reynolds, RJ Sullivan, JM Balko, JR Patrinely, ...
The Lancet Oncology 21 (8), e398-e404, 2020
Các cơ quan ủy nhiệm: US National Institutes of Health
Immune checkpoint blockade
J Naidoo, DB Page, JD Wolchok
Hematology/Oncology Clinics 28 (3), 585-600, 2014
Các cơ quan ủy nhiệm: US National Institutes of Health
Information visualization platform for postmarket surveillance decision support
J Spiker, K Kreimeyer, O Dang, D Boxwell, V Chan, C Cheng, P Gish, ...
Drug Safety 43, 905-915, 2020
Các cơ quan ủy nhiệm: US National Institutes of Health
Có tại một số nơi: 85
Neoadjuvant PD-1 blockade in resectable lung cancer
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
Các cơ quan ủy nhiệm: US National Institutes of Health, LUNGevity Foundation, USA
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
Các cơ quan ủy nhiệm: US National Institutes of Health, Fonds de recherche du Québec - Santé
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J Naidoo, DB Page, BT Li, LC Connell, K Schindler, ME Lacouture, ...
Annals of Oncology 26 (12), 2375-2391, 2015
Các cơ quan ủy nhiệm: US National Institutes of Health
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ...
Journal of Clinical Oncology 39 (36), 4073-4126, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health
Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709-717, 2017
Các cơ quan ủy nhiệm: US National Institutes of Health
Genome-wide cell-free DNA fragmentation in patients with cancer
S Cristiano, A Leal, J Phallen, J Fiksel, V Adleff, DC Bruhm, SØ Jensen, ...
Nature 570 (7761), 385-389, 2019
Các cơ quan ủy nhiệm: US National Institutes of Health, Danish Council for Independent Research …
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, ...
Journal of Clinical Oncology 40 (12), 1301-1311, 2022
Các cơ quan ủy nhiệm: US National Institutes of Health, National Institute for Health Research, UK
Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer
V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ...
Cancer discovery 7 (3), 264-276, 2017
Các cơ quan ủy nhiệm: US National Institutes of Health, Dutch Cancer Society, LUNGevity Foundation …
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
JR Brahmer, H Abu-Sbeih, PA Ascierto, J Brufsky, LC Cappelli, ...
Journal for immunotherapy of cancer 9 (6), e002435, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health
Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial
C Faivre-Finn, D Vicente, T Kurata, D Planchard, L Paz-Ares, ...
Journal of Thoracic Oncology 16 (5), 860-867, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health, National Institute for Health Research, UK
Cardiovascular toxicities associated with immune checkpoint inhibitors
JR Hu, R Florido, EJ Lipson, J Naidoo, R Ardehali, CG Tocchetti, AR Lyon, ...
Cardiovascular research 115 (5), 854-868, 2019
Các cơ quan ủy nhiệm: US National Institutes of Health
Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma–like and non–small cell carcinoma–like subsets
N Rekhtman, MC Pietanza, MD Hellmann, J Naidoo, A Arora, H Won, ...
Clinical Cancer Research 22 (14), 3618-3629, 2016
Các cơ quan ủy nhiệm: US National Institutes of Health
Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors
K Suresh, KR Voong, B Shankar, PM Forde, DS Ettinger, KA Marrone, ...
Journal of Thoracic Oncology 13 (12), 1930-1939, 2018
Các cơ quan ủy nhiệm: US National Institutes of Health
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
LC Cappelli, AK Gutierrez, AN Baer, J Albayda, RL Manno, U Haque, ...
Annals of the rheumatic diseases 76 (1), 43-50, 2017
Các cơ quan ủy nhiệm: US National Institutes of Health
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ...
Nature 596 (7870), 126-132, 2021
Các cơ quan ủy nhiệm: US National Institutes of Health, LUNGevity Foundation, USA, Damon Runyon …
Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer
B Shankar, J Zhang, AR Naqash, PM Forde, JL Feliciano, KA Marrone, ...
JAMA oncology 6 (12), 1952-1956, 2020
Các cơ quan ủy nhiệm: US National Institutes of Health
Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities
K Suresh, J Naidoo, CT Lin, S Danoff
Chest 154 (6), 1416-1423, 2018
Các cơ quan ủy nhiệm: US National Institutes of Health
Chương trình máy tính sẽ tự động xác định thông tin xuất bản và thông tin về nhà tài trợ